Results 131 to 140 of about 68,648 (313)

Insights from a six‐year hair drug analysis compendium in drug‐facilitated crimes involving vulnerable population cases

Journal of Forensic Sciences, EarlyView.
Abstract Hair analysis is a well‐established matrix in forensic toxicology, offering a valuable alternative or complement to traditional matrices in diverse contexts, including drug‐facilitated crimes (DFC), elder abuse, and accidental exposure in children.
Amandine Fort, Coralie Boudin, Hélène Eysseric‐Guerin, Virginie Scolan, François Paysant, Cloé Scherpereel, Mélissa Revet, Françoise Stanke‐Labesque, Théo Willeman   +8 more
wiley   +1 more source

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Th-ThC Phase Diagram

, 2010
application/pdfThe partial phase diagram in the Th-C system between pure Th and ThC was studied by metallographic and X-ray techniques and by measurements of electrical resistivity in quenched and slow cooled Th-C alloys.
HONMA, Toshio, HIRAI, Toshio, TAKEUCHI, Sakae, SATOW, Tsuneo   +3 more
core  

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Observational Analysis of the Influence of Medical Marijuana Use on Quality of Life in Patients

Medical Cannabis and Cannabinoids
Introduction: A significant gap exists in the understanding and utilization of medical marijuana and its effects on a patient’s quality of life. This is largely attributed to Cannabis’ sp.
Mark D. Kelley, Marwah Obaid, Edward M. Miller, Marla Bowie, Zachary S. Heeter   +4 more
doaj   +1 more source

Cannabis dispensary exposure and smoked, vaped and edible cannabis use among young adults: Comparison of web‐scraped and government‐maintained registries

Addiction, EarlyView.
Abstract Background and aims The impact of exposure to cannabis dispensaries on young adult cannabis use may depend on how exposures and outcomes are defined. We estimated associations of dispensary exposure with young adult cannabis use across: (a) a government‐maintained licensed dispensaries registry versus a web‐scraped list of licensed and ...
Alyssa F. Harlow, Michael P. Williams, Rosalie Liccardo Pacula, Adam M. Leventhal, Eric R. Pedersen, Myles G. Cockburn, Laura K. Thompson, Junhan Cho, Jessica L. Barrington‐Trimis, Danielle F. Haley   +9 more
wiley   +1 more source

The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis

Addiction, EarlyView.
Abstract Background and aims The global cannabidiol (CBD) market has expanded in recent years. Several studies suggest CBD use, whether for medical or recreational purposes, is on the rise; however, no systematic assessments of its prevalence have been conducted so far. This meta‐analysis aimed to estimate the prevalence of CBD use in North America and
Sara Weidberg, Clara Iza‐Fernández, Layla Alemán‐Moussa, Andrea Krotter, Alba González‐Roz   +4 more
wiley   +1 more source

Cannabis for Neuropathic Pain in Multiple Sclerosis—High Expectations, Poor Data

Frontiers in Pharmacology, 2019
Thorsten Rudroff, Thorsten Rudroff
doaj   +1 more source

Evaluation of THC-induced neurotoxicity via oxidative stress in undifferentiated SH-SY5Y cells

The increasing global consumption of cannabis, particularly high-THC products, has raised public health concerns due to potential neurotoxic effects, although its association with oxidative stress remains a subject of debated.
Fraguas Sánchez, Ana Isabel, Serrano López, Dolores Remedios, González Burgos, Elena María, Pérez Pérez, Teresa, Basilicata, Pascale, Pieri, María, Anaya, Brayan Javier, Sanz-Pérez, Amadeo   +7 more
core   +1 more source